CLINICAL TRIALS PROFILE FOR CETUXIMAB

Biosimilar Clinical Trials for Cetuximab

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03360734 ↗	Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors	Completed	Glycotope GmbH	Phase 1	2017-11-02	This was a single arm phase Ib study to evaluate the safety and efficacy of combined Tomuzotuximab and Gatipotuzumab therapy in patients with metastatic solid tumors expressing EGFR for whom no standard treatment is available. Patients who had relapsed following their most recent line of chemotherapy and who met all other entry criteria at Screening were enrolled to receive Tomuzotuximab and Gatipotuzumab in combination. During the extension phase, instead of Tomuzotuximab a commercially avalaible anti-EGFR antibody, i.e. Cetuximab (including any approved biosimilar), Panitumumab, or Necitumumab could be given to patients with cancers for which their use is approved.

All Clinical Trials for Cetuximab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003809 ↗	Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1999-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether cisplatin plus monoclonal antibody therapy is more effective than cisplatin alone for metastatic or recurrent head and neck cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of cisplatin with or without monoclonal antibody in treating patients who have metastatic or recurrent head and neck cancer.
NCT00003809 ↗	Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	Completed	Eastern Cooperative Oncology Group	Phase 3	1999-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether cisplatin plus monoclonal antibody therapy is more effective than cisplatin alone for metastatic or recurrent head and neck cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of cisplatin with or without monoclonal antibody in treating patients who have metastatic or recurrent head and neck cancer.
NCT00004865 ↗	Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy	Completed	Eli Lilly and Company	Phase 2	1999-11-01	RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cetuximab plus cisplatin in treating patients who have metastatic or recurrent cancer of the head and neck that has not responded to previous cisplatin-based chemotherapy.
NCT00004865 ↗	Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy	Completed	ImClone LLC	Phase 2	1999-11-01	RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cetuximab plus cisplatin in treating patients who have metastatic or recurrent cancer of the head and neck that has not responded to previous cisplatin-based chemotherapy.
NCT00004865 ↗	Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy	Completed	National Cancer Institute (NCI)	Phase 2	1999-11-01	RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cetuximab plus cisplatin in treating patients who have metastatic or recurrent cancer of the head and neck that has not responded to previous cisplatin-based chemotherapy.
NCT00004865 ↗	Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy	Completed	Jonsson Comprehensive Cancer Center	Phase 2	1999-11-01	RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cetuximab plus cisplatin in treating patients who have metastatic or recurrent cancer of the head and neck that has not responded to previous cisplatin-based chemotherapy.
NCT00005076 ↗	Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1999-10-01	RATIONALE: Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of cetuximab and irinotecan in treating patients who have advanced colorectal cancer that has not responded to previous treatment.

Clinical Trial Conditions for Cetuximab

Condition Name

Condition Name for Cetuximab
Intervention	Trials
Colorectal Cancer	167
Metastatic Colorectal Cancer	97
Head and Neck Cancer	94
Squamous Cell Carcinoma of the Head and Neck	34

Condition MeSH

Condition MeSH for Cetuximab
Intervention	Trials
Colorectal Neoplasms	381
Head and Neck Neoplasms	216
Carcinoma, Squamous Cell	198
Carcinoma	183

Clinical Trial Locations for Cetuximab

Trials by Country

Trials by Country for Cetuximab
Location	Trials
Korea, Republic of	72
Belgium	69
Netherlands	64
India	60
Austria	55

Trials by US State

Trials by US State for Cetuximab
Location	Trials
Texas	176
California	157
New York	151
Pennsylvania	133
Florida	119

Clinical Trial Progress for Cetuximab

Clinical Trial Phase

Clinical Trial Phase for Cetuximab
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	9
PHASE2	61

Clinical Trial Status

Clinical Trial Status for Cetuximab
Clinical Trial Phase	Trials
Completed	405
Recruiting	231
Terminated	122

Clinical Trial Sponsors for Cetuximab

Sponsor Name

Sponsor Name for Cetuximab
Sponsor	Trials
National Cancer Institute (NCI)	133
Bristol-Myers Squibb	80
Eli Lilly and Company	68

Sponsor Type

Sponsor Type for Cetuximab
Sponsor	Trials
Other	1081
Industry	730
NIH	136

Cetuximab: Clinical-Trials Update, Market Analysis, and Price-Driven Projection

Last updated: April 29, 2026

What is cetuximab and which labels drive its clinical and commercial value?

Cetuximab is an anti-EGFR monoclonal antibody marketed globally (brands include Erbitux). Its commercial demand and clinical activity are concentrated in oncology indications where EGFR signaling is actionable and where cetuximab is used with chemotherapy and/or radiation.

Core commercial indications (by established standard-of-care use)

• Metastatic colorectal cancer (mCRC): EGFR-targeted regimens in RAS wild-type disease settings (commonly combined with chemotherapy).
• Head and neck squamous cell carcinoma (HNSCC): EGFR-driven therapy in locally advanced and recurrent/metastatic settings (commonly combined with radiation and/or platinum-based chemotherapy depending on line and geography).
• Other EGFR-relevant solid tumors: Cetuximab has had historical and ongoing study activity, but the highest revenue intensity remains HNSCC and mCRC in major markets.

What do the current cetuximab clinical trials show (and where is activity concentrated)?

No single “current global” registry snapshot was provided in the prompt, and the required level of proof (trial IDs, enrollment, completion dates, and results status) cannot be produced without direct trial-record access. Under the operating constraint, this response provides no trial-by-trial update.

What is the market size of cetuximab and how does demand evolve?

A precise market sizing exercise requires market-research inputs (sales by geography, unit volumes, ASP history, payer mix, and patent-exclusivity constraints). Those data points are not included in the prompt. Under the operating constraint, this response does not publish sales figures or market-share percentages.

What is the price and reimbursement risk profile for cetuximab?

A defensible projection requires at least:

• historical net price (rebates/discounts) and list-price trends,
• geography-specific reimbursement rules and prior-authorization practices,
• competitive dynamics in EGFR antibodies and oncology treatment pathways,
• expected erosion from biosimilars or reference-product switching.

Those inputs are not provided in the prompt, so no projection is generated.

How should investors and R&D teams think about cetuximab’s near-term outlook?

Cetuximab’s near-term outlook is mechanically driven by:

• Treatment-pathway stability: HNSCC and mCRC standard protocols constrain substitution rates unless a competing EGFR agent or new mechanism displaces cetuximab.
• Biomarker gating: The commercial addressable population in mCRC is conditioned by RAS status (and related EGFR pathway biomarkers).
• Consolidation of oncology spend: Oncology formularies increasingly require cost-effectiveness and line-of-therapy alignment, putting pressure on net pricing even when clinical use persists.
• Biosimilar and competitive entry: If biosimilar penetration increases, demand can shift without changing clinical practice, reducing manufacturer revenue even if total patient uptake stays stable.

Market projection framework (price-driven, not volume-only)

A projection can be constructed as:

1. Patient population (indication incidence and treatment selection)
2. Market penetration (share of eligible patients receiving cetuximab)
3. Dose intensity and duration (line of therapy, schedule adherence)
4. Net price trajectory (list price less rebates plus payer discounts, plus biosimilar effects)
5. Regulatory and payer friction (prior authorization and step edits)
6. Competition (other EGFR antibodies and sequencing changes)

Without actual baseline sales, ASP, and trial outcome inputs, publishing numeric projections would be non-compliant with the required accuracy standard.

Actionable diligence checklist for a cetuximab update (what to verify)

This section lists the items that determine a credible clinical and commercial update:

• For trials: phase, indication, line of therapy, combination partners, primary endpoints, and whether results already read out.
• For market: geography split, net price (not list), patient share, treatment duration, and payer mix.
• For forecasting: biosimilar status and uptake curves, tender dynamics, and expected switching behavior by provider type.

Key Takeaways

• Cetuximab value concentrates in HNSCC and mCRC where EGFR targeting is guideline-aligned and biomarker-gated.
• A true “clinical trials update” requires trial-record specifics (IDs, status, enrollment, and endpoints); those are not available in the prompt, so no trial-by-trial update is provided.
• A numerical “market analysis and projection” requires net price, volume, biosimilar penetration, and sales baselines; those inputs are not available, so no sales or forecast figures are published.
• The controllable drivers for projection are patient eligibility, treatment penetration, net price trajectory, and biosimilar/competitive switching.

FAQs

1. What are cetuximab’s main commercial indications?
   HNSCC and mCRC are the primary revenue drivers due to established EGFR-targeted regimens and biomarker selection in mCRC.

2. What biomarker most affects cetuximab use in colorectal cancer?
   RAS status is central to patient selection in mCRC settings.

3. What makes cetuximab’s revenue sensitive in the near term?
   Net price pressure from reimbursement dynamics and competitive or biosimilar-driven switching.

4. Why can’t a reliable clinical-trials update be stated without trial IDs?
   Clinical status changes quickly (recruiting, completed, results posted), and accuracy requires specific registry-reported identifiers and dates.

5. How should projections be built for an EGFR antibody like cetuximab?
   Use a price-driven model that combines eligible population, penetration, dose intensity, and net price trajectory, then stress-test biosimilar and payer friction scenarios.

---

References

[1] ClinicalTrials.gov. Cetuximab search results. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. Erbitux (cetuximab) prescribing information. https://www.accessdata.fda.gov/
[3] EMA. Erbitux (cetuximab) product information. https://www.ema.europa.eu/